Enerflex Ltd. Reports Fourth Quarter 2023 Financial and Operational Results

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

ADJUSTED EBITDA OF $126 MILLION AND $185 MILLION OF FREE CASH FLOW ENGINEERED SYSTEMS BACKLOG OF $1.5 BILLION PROVIDES SOLID VISIBILITY FOR 2024 REPAID $167 MILLION OF DEBT AND REDUCED NET DEBT-TO-EBITDA RATIO1 TO 2.3 TIMES AT YEAR END CALGARY, Alberta, Feb. 28, 2024 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today reported its financial and operational results for the three months and year ended December 31, 2023. All amounts are presented in Canadian dollars unless otherwise stated. Q4 2023 FINANCIAL AND OPERATIONAL OVERVIEW Generated revenue of $782 million compared to $778 million in Q3/2023, with results driven by continued strong performance from recurring businesses. Increased gross margin before depreciation and amortization to $216 million, or 27.7% of revenue, compared to...

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 Organic revenue was $48.8 million, representing an increase of 1% compared to the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation (“Luminex”) on February 28, 2023 was $9.8 million Total revenue was $193.4 million, or $194.1 million on a non-GAAP constant currency basis, for the full year 2023,...

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Written by Customer Service on February 28, 2024. Posted in Public Companies.

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024. A live audio webcast of the panel discussion will be available on the Investors section of the atai website under Events. A replay of the webcast will be available following the live event. About atai Life Sciencesatai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing...

Savaria Announces Date for Fourth Quarter 2023 Financial Results

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

LAVAL, Quebec, Feb. 28, 2024 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, announces it will release its financial results for the fourth quarter of 2023 after market close on March 6, 2024. Savaria’s management will hold an investor conference call and webcast at 8:30 a.m. Eastern Time (ET) on Thursday, March 7, 2024. Investors and members of the media are invited to participate on a listen-only basis. Conference call access: https://register.vevent.com/register/BI6a2d99af8ce145029a2ec0e3fe3f52d6 To access the conference call, you must register online and choose the method to join the call, either by dialing the number provided to you or by entering your phone number to receive a call from the system. Webcast URL (EN): https://edge.media-server.com/mmc/p/jivftqsd About...

WSP Reports Strong 2023 Results and Outlook for 2024

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

2023 ACCOMPLISHMENTS: Strong results in the high end of Management’s revised outlook range Net revenue up 22% or nearly $2B resulting from strong organic growth of 7.3% and strategic acquisitions Adjusted EBITDA up 26% or nearly $400M Adjusted EBITDA margin at 17.6%, up 55 bps, beyond strategic ambitions of 30 to 50 bps Adjusted net earnings up 24%, resulting from accretive acquisitions and productivity gains Record-high order intake of $15.1 billion, reflecting continued strong market conditions Fourth-quarter net revenue organic growth of 5.1% and robust adjusted EBITDA margin increase of 150 bps Successful consolidation of recent strategic acquisitions substantially completed Strong balance sheet supporting continued growth aspirations Positioned to exceed 2024 strategic financial ambitions MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE)...

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended...

Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

Written by Customer Service on February 28, 2024. Posted in Public Companies.

ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET at the Marriott Copley Place in Boston, Mass. Investors interested in arranging a meeting with company management during the conference should contact the TD Cowen conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived...

Aimfinity Investment Corp. I Announces Eighth Extension of the Deadline for an Initial Business Combination to March 28, 2024

Written by Customer Service on February 28, 2024. Posted in Public Companies.

Wilmington, Delaware, Feb. 28, 2024 (GLOBE NEWSWIRE) — Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company incorporated as a Cayman Islands exempted company, today announced that, in order to extend the date by which the Company mush complete its initial business combination from February 28, 2024 to March 28, 2024, I-Fa Chang, sole member and manager of the sponsor of the Company, has deposited into its trust account (the “Trust Account”) an aggregate of $85,000 (the “Monthly Extension Payment”). Pursuant to the Company’s second amended & restated memorandum and articles of association (“Current Charter”), effectively July 27, 2023, the Company may extend on a monthly basis from July 28, 2023 until April 28, 2024 or such an earlier date as may be determined by its...

Dycom Industries, Inc. to Participate in Upcoming Investor Conferences

Written by Customer Service on February 28, 2024. Posted in Public Companies.

PALM BEACH GARDENS, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) — Dycom Industries, Inc. (NYSE: DY) today announced that the Company will be participating in the following upcoming investor conferences: Tuesday, March 5, 2024 – Raymond James 45th Annual Institutional Investors Conference, Orlando, FLSteve Nielsen, President and Chief Executive Officer, will present in a fireside chat format at 8:40 a.m. ET. Additionally, senior management will participate in one-on-one and group meetings with investors. Wednesday, March 6, 2024 – UBS Global Banking Services Conference, New York, NYSteve Nielsen, President and Chief Executive Officer, will participate in a panel at 12:15 p.m. ET available to live attendees titled “Pulse of the Specialty Contracting Service Market” Tuesday, March 19, 2024 – TD Cowen’s 3rd Annual Fiber-to-the-Home Symposium,...

Interpublic Group to Present at the 2024 Morgan Stanley Technology, Media & Telecom Conference

Written by Customer Service on February 28, 2024. Posted in Public Companies.

New York, NY, Feb. 28, 2024 (GLOBE NEWSWIRE) — Interpublic Group (NYSE: IPG) senior management will present at the 2024 Morgan Stanley Technology, Media & Telecom Conference on Tuesday, March 5th, 2024, at 6:35 pm Eastern time/3:35 pm Pacific Time, as scheduled. A link to the live webcast will be posted on the day of the conference on the Investor Relations section of Interpublic’s website (http://investors.interpublic.com) where it will remain available for replay for 30 days. # # # About InterpublicInterpublic (NYSE: IPG) (www.interpublic.com) is a values-based, data-fueled, and creatively-driven provider of marketing solutions. Home to some of the world’s best-known and most innovative communications specialists, IPG global brands include Acxiom, Craft, FCB, FutureBrand, Golin, Huge, Initiative, IPG Health, IPG Mediabrands,...

Day: February 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice